Stock listing

NASDAQ:CGEM Cullinan Therapeutics, Inc. Stock

Home listing (NASDAQ) of Cullinan Therapeutics, Inc.

Follow Cullinan Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CGEM

$8.89 USD -0.12 (-1.3%)

Close on Nov 20, 2026

Past year +1.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.80 – $9.43 USDNov 20, 2026
Volume
1.01M sharesNov 20, 2026
Market cap
$577.1M USDAt the close on Nov 20, 2026 · price × 64.92M shares outstanding
52-week range
$8.48 – $23.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$16.02M USDMedian day 831,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cullinan Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CGEM · Home$8.89 USD-0.12 (-1.3%)1,009,932$8.84$9.43$8.80$9.01Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CGEM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.89-0.12-1.3%$8.84$9.43$8.801,009,932
$9.01-0.265-2.9%$9.17$9.514$8.811,063,904
$9.275-0.225-2.4%$9.45$9.45$8.4751,625,986
$9.50-0.78-7.6%$10.11$10.28$9.46866,715
$10.28+0.09+0.9%$10.19$10.35$9.761,376,903
$10.19-1.16-10.2%$11.04$11.12$10.111,135,106
$11.35+0.12+1.1%$11.34$11.68$11.15982,590
$11.23-0.50-4.3%$11.71$12.04$10.95810,360
$11.73+0.42+3.7%$11.40$12.41$10.801,035,134
$11.31+0.51+4.7%$11.09$11.77$10.69755,506
$10.80-1.69-13.5%$12.36$12.48$10.771,789,228
$12.49-3.26-20.7%$15.99$16.29$11.922,203,294
$15.75+0.82+5.5%$15.04$16.20$14.98788,705
$14.93-0.10-0.7%$15.13$15.35$14.63730,766
$15.03-0.42-2.7%$15.38$15.72$14.70389,400
$15.45-0.11-0.7%$15.60$16.19$15.35459,700
$15.56+0.72+4.9%$14.93$15.62$14.72594,200
$14.84+0.30+2.1%$14.66$14.98$14.28488,100
$14.54+0.17+1.2%$14.71$14.87$14.39438,500
$14.37-0.55-3.7%$14.95$14.95$13.86485,200
$14.92+0.03+0.2%$14.82$15.32$14.64392,700
$14.89+0.06+0.4%$14.92$15.26$14.64691,000
$14.83+0.85+6.1%$13.92$14.92$13.85694,000
$13.98+1.05+8.1%$13.02$14.00$12.77862,500
$12.93-1.07-7.6%$13.91$13.91$12.811,123,300
$14.00+0.36+2.6%$13.62$14.18$13.46972,100
$13.64-0.46-3.3%$13.81$14.18$13.44903,500
$14.10-0.85-5.7%$14.86$14.93$14.08590,300
$14.95-0.58-3.7%$15.45$15.64$14.88372,400
$15.53+0.07+0.5%$15.41$15.95$15.24567,500
$15.46-0.17-1.1%$15.60$15.71$14.811,137,400
$15.63-0.62-3.8%$15.95$16.46$15.47808,200
$16.25+0.21+1.3%$17.24$17.70$16.062,017,000
$16.04+0.53+3.4%$15.59$16.55$15.131,083,000
$15.51+0.98+6.7%$14.76$15.56$14.591,162,100
$14.53-0.82-5.3%$15.22$15.39$14.49910,800
$15.35+0.12+0.8%$15.39$15.78$14.961,067,200
$15.23+0.28+1.9%$15.00$15.44$14.681,244,400
$14.95+0.14+0.9%$14.71$15.19$14.201,109,200
$14.81-0.63-4.1%$15.62$15.62$14.671,715,500
$15.44-1.43-8.5%$16.60$16.88$14.802,728,800
$16.87-4.80-22.2%$21.67$21.67$16.782,593,300
$21.67+0.32+1.5%$21.44$21.88$21.27831,800
$21.35+0.27+1.3%$21.45$21.79$20.98763,900
$21.08-0.28-1.3%$21.38$21.45$20.633,251,000
$21.36+0.73+3.5%$21.06$21.58$20.81756,700
$20.63+0.09+0.4%$20.50$20.84$20.20825,700
$20.54+0.14+0.7%$20.38$20.71$19.641,060,500
$20.40-0.19-0.9%$18.55$20.93$18.511,418,200
$20.59-0.41-2.0%$21.16$21.34$20.101,090,400
$21.00-0.31-1.5%$20.99$21.22$20.50805,600
$21.31-0.38-1.8%$21.30$21.80$21.081,278,700
$21.69-0.40-1.8%$21.61$22.41$21.28953,700
$22.09-0.07-0.3%$21.88$22.30$21.77562,200
$22.16-0.17-0.8%$22.39$22.68$21.65524,100
$22.33+0.54+2.5%$21.88$22.79$21.75769,700
$21.79-0.28-1.3%$21.80$22.07$21.55546,100
$22.07+0.37+1.7%$21.50$22.23$21.34682,500
$21.70-0.90-4.0%$22.60$22.88$21.57630,100
$22.60-0.25-1.1%$22.55$22.96$22.19471,900
$22.85-0.10-0.4%$22.66$23.19$22.42683,300
$22.95+1.13+5.2%$22.16$23.06$22.16519,255
$21.82+0.14+0.6%$21.62$22.37$21.16617,367
$21.68+0.30+1.4%$21.72$22.11$21.40758,100
$21.38-1.14-5.1%$22.14$22.25$21.02902,500

Splits

1 split · NASDAQ:CGEM · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
Ticker
NASDAQ:CGEM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cullinan Therapeutics, Inc. news

Cullinan Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 130 in all · newest Nov 12, 2026 · oldest 2021
Decks
22 decks · latest October 2026

Where Cullinan Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CGEM · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CGEMBOATSUnited StatesUSD

Valuation

Price/book 2.0× against a median of 2.4×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$289.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.45

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cullinan Therapeutics, Inc. · NASDAQ:CGEMUS$577.1MUS$289.6Mn/an/an/a2.0×n/a0.0×1.45
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.6Mn/a106×n/a2.9×n/a0.4×n/a
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Design Therapeutics, Inc. · NASDAQ:DSGNUS$577.6MUS$371.5Mn/an/an/a2.9×n/a0.0×1.29
Immix Biopharma, Inc. · NASDAQ:IMMXUS$577.0MUS$241.7Mn/an/an/a1.7×n/a0.0×1.60
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
DBV Technologies SA · EURONEXT:DBVUS$571.8MUS$430.7Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.3MUS$232.4Mn/a765×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.8MUS$613.4M14.6×4.5×22.9×2.6×28.0%0.8×n/a
Median of the othersUS$573.3MUS$340.2M14.6×47.1×22.9×2.4×−90.3%0.0×1.49

Forecasts

11 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
34.70 USD · Analysts' mean
EPS, year to Dec 2026
-2.98 · 4 analysts

Team and board

Officers

OfficerRole
Nadim AhmedPresident and Chief Executive Officer

Board

DirectorRole
Andrew AllenMember of the Compensation Committee
David MeekChair of the Nominating and Corporate Governance Committee
Mary ThistleChair of the Compensation Committee
Mittie DoyleMember of the Nominating and Corporate Governance Committee
Stephen WebsterChair of the Audit Committee
Tony RosenbergMember of the Audit Committee

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−4.3%
Q2 2026Aug 6, 2026 · Before open+1.9%
Q1 2026May 7, 2026 · Before open−1.8%
Q4 2025Mar 5, 2026−3.4%
Q3 2025Nov 6, 2025 · Before open+0.6%
Q2 2025Aug 7, 2025 · Before open−10.8%
Q1 2025May 8, 2025 · Before open+0.9%
Q4 2024Mar 12, 2025 · Before open+4.7%
Q3 2024Nov 7, 2024 · Before open−5.5%
Q2 2024Aug 8, 2024 · Before open−1.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close−10.9%
Q4 2023Mar 14, 2024 · Before open−0.4%
Q3 2023Nov 8, 2023 · Before open+0.8%
Q2 2023Aug 10, 2023 · Before open−0.7%
Q1 2023May 11, 2023 · After close+1.5%
Q4 2022Mar 9, 2023 · Before open+0.1%
Q3 2022Nov 14, 2022 · Before open+2.4%
Q2 2022Aug 10, 2022 · Before open−0.8%
Q1 2022May 16, 2022 · Before open+2.5%
Q4 2021Mar 17, 2022 · Before open+4.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck64 slidesOctober 2026
WCLC 2026Conference15 slidesSeptember 2026
Investor Presentation (September 2025)Investor deck53 slidesSep 4, 2025
Technical Presentation (September 2025)Technical17 slidesSeptember 2025
Technical Presentation (September 2025)Technical14 slidesSeptember 2025
Merger or Acquisition (June 2025)Merger or acquisition17 slidesJun 4, 2025
Investor Presentation (April 2025)Investor deck58 slidesApr 16, 2025
Investor Presentation (April 2025)Investor deck87 slidesApr 16, 2025
Investor Presentation (February 2025)Investor deck57 slidesFeb 27, 2025
Investor Presentation (January 2025)Investor deck57 slidesJan 28, 2025
All 22 decks
DeckKindSlidesDate
Investor Presentation (October 2024)Investor deck55 slidesOct 16, 2024
Investor Presentation (September 2024)Investor deck51 slidesSep 17, 2024
Corporate Update (June 2024)Corporate update35 slidesJun 3, 2024
Investor Presentation (June 2024)Investor deck48 slidesJune 2024
Investor Presentation (May 2024)Investor deck38 slidesMay 15, 2024
Corporate Update (April 2024)Corporate update25 slidesApr 16, 2024
Investor Presentation (April 2024)Investor deck37 slidesApr 16, 2024
Cullinan Oncology — Corporate Update (May 2022)Corporate update10 slidesMay 12, 2022
Cullinan Oncology — Technical Presentation (December 2021)Technical18 slidesDec 16, 2021
Cullinan Oncology — Informa AET (December 2021)Conference18 slidesDec 14, 2021
Cytokine Summit (September 2021)Conference12 slidesSep 22, 2021
Cullinan Oncology — Technical Presentation (June 2021)Technical17 slidesJun 4, 2021

Open Decks

IPO

Went public as Cullinan Management, Inc. Priced at US$21.00 a share on Jan 7, 2021.

Price
US$21.00 a share
Shares offered
11,900,000 shares of common stock
Offering size
US$249.9 million
Underwriters' option
Up to 1,785,000 more shares
Underwriters
MORGAN STANLEY, SVB LEERINK, EVERCORE ISI, H.C. WAINWRIGHT & CO. · In the order on the cover
Shares delivered
On or about Jan 12, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceNov 2, 2020
Filed publiclyDec 18, 2020
Amended 3 timesNewest Jan 6, 2021
Shares registered with an exchangeJan 6, 2021
Declared effective by the SECJan 7, 2021
Final prospectus, with the priceJan 11, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jan 11, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Revenue000018.9M00000
Cost of revenue311.0K306.0K310.0K93.0K53.0K62.0K70.0K43.0K00
Gross profit-311.0K-306.0K-310.0K-93.0K18.9M-62.0K-70.0K-43.0K00
Research and development187.4M142.9M148.2M91.9M57.8M43.2M16.8M9.58M
Selling, general and administrative54.2M52.8M42.5M40.2M29.1M17.1M5.48M5.00M197.4K95.4K
Operating income-241.6M-196.9M-191.1M144.6M-68.0M-60.3M-22.3M-14.6M-197.4K-95.4K
Depreciation and amortization311.0K306.0K310.0K93.0K53.0K62.0K70.0K43.0K
EBITDA-241.3M-196.6M-190.8M144.7M-67.9M-60.3M-22.2M-14.5M
Interest expense562.4M65.4M888.0K0000
Income before tax-219.9M-167.5M-169.2M151.3M-67.5M-59.5M-21.7M-14.2M-316.7K-109.5K
Income tax0117.0K-14.1M42.1M0-8.61M-1.62M397.0K00
Net income-219.9M-167.4M-153.2M111.2M-65.6M-51.8M-20.0M-14.2M-316.7K-109.5K
Earnings per share, basic-3.65-2.86-3.692.46-1.52-2.60-19.68-17.74
Earnings per share, diluted-3.692.38-1.52-2.60

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Cash and equivalents88.3M83.0M98.4M156.2M59.8M168.2M63.3M33.8M91118
Short-term investments289.6M316.0M368.6M311.1M230.7M42.0M35.4M0
Receivables3.00M5.40M3.34K
Inventory-5.40M
Current assets386.8M414.7M480.2M474.5M296.6M212.3M100.1M34.2M3.44K118
Property, plant and equipment421.0K683.0K989.0K1.17M77.0K130.0K182.0K233.0K
Total assets448.4M621.8M484.2M561.1M437.2M214.7M100.5M34.6M3.44K118
Accounts payable841.0K1.68M2.49M2.66M3.17M9.68M934.0K296.0K247.9K156.7K
Current liabilities37.7M30.6M28.1M22.5M11.7M14.3M2.52M1.32M247.9K156.7K
Long-term debt330.4K1.09M
Total debt2.68M2.15M3.59M5.19M
Total liabilities39.6M31.5M30.3M26.1M11.8M14.4M140.4M55.3M578.3K1.24M
Shareholders' equity408.7M590.3M453.7M535.0M425.0M199.0M-40.8M-20.7M-574.9K-1.24M
Shares outstanding60.2M58.5M42.9M45.8M44.3M29.8M1.02M800.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Cash from operations-175.8M-145.3M-134.3M-126.7M-43.4M-29.8M-20.9M-13.5M-228.9K-24.0K
Capital spending-49.0K0-208.0K-1.13M0-10.0K-20.0K-261.0K00
Free cash flow-175.8M-145.3M-134.5M-127.8M-43.4M-29.8M-20.9M-13.8M-228.9K-24.0K
Cash from investing180.0M-136.3M35.8M249.0M-333.8M-5.42M-35.4M-261.0K
Cash from financing1.09M266.2M40.8M-25.9M268.8M140.1M85.7M-29.0K228.9K22.0K
Share buybacks-23.7M271.5M-6.57M-378.0K-21.0K986.7K986.7K
Change in cash5.33M-15.4M-57.7M96.4M-108.4M104.9M29.4M-13.8M-27-2.05K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026Current reportSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
144 · Notice of proposed saleNov 5, 2026Other filingsSEC
8-K · Current reportNov 4, 2026Current reportSEC
8-K · Current reportOct 1, 2026Current reportSEC
8-K · Current reportSep 24, 2026Current reportSEC
8-K · Current reportSep 14, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 10, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
8-K · Current reportAug 12, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 16, 2026Meeting outcomeSEC
8-K · Current reportJun 10, 2026Current reportSEC
8-K · Current reportJun 8, 2026Current reportSEC
8-K · Current reportMay 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
S-3ASR · Registration statementApr 28, 2026Offer documentSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 10, 2026Offer documentSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMar 4, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
8-K · Current reportJan 8, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
8-K · Current reportDec 8, 2025Current reportSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
8-K · Current reportNov 21, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportNov 3, 2025Current reportSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 10, 2025Big-stake noticeSEC
8-K · Current reportSep 4, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 8, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 8, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
8-K · Current reportJun 4, 2025Material contractSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
8-K · Current reportJan 29, 2025Current reportSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 31, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
8-K · Current reportOct 16, 2024Current reportSEC
8-K · Current reportSep 17, 2024Current reportSEC
4 · Change in ownershipSep 9, 2024Insider tradeSEC
144 · Notice of proposed saleSep 5, 2024Other filingsSEC
3 · Initial statement of ownershipAug 9, 2024Insider tradeSEC
4 · Change in ownershipAug 9, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipJul 9, 2024Insider tradeSEC
144 · Notice of proposed saleJul 5, 2024Other filingsSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
8-K · Current reportJun 27, 2024Meeting outcomeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJun 7, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 5, 2024Other filingsSEC
424B3 · ProspectusJun 4, 2024Offer documentSEC
8-K · Current reportJun 3, 2024Current reportSEC
CORRESP · Letter to the SECMay 31, 2024Other filingsSEC
8-K · Current reportMay 23, 2024Current reportSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
UPLOAD · Letter from the SECMay 20, 2024Other filingsSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 16, 2024Insider tradeSEC
S-3 · Registration statementMay 16, 2024Offer documentSEC
ARS · Annual report to shareholdersMay 16, 2024Annual reportSEC
DEFA14A · Additional proxy materialMay 16, 2024Meeting noticeSEC
DEF 14A · Proxy statementMay 16, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
144 · Notice of proposed saleMay 6, 2024Other filingsSEC
4 · Change in ownershipApr 30, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2024Insider tradeSEC
8-K · Current reportApr 29, 2024Management or board changeSEC
SC 13G · Big-stake noticeApr 24, 2024Big-stake noticeSEC
8-K · Current reportApr 16, 2024Material contractSEC
3 · Initial statement of ownershipApr 2, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 14, 2024Offer documentSEC
10-K · Annual reportMar 14, 2024Annual reportSEC
8-K · Current reportMar 14, 2024ResultsSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC

This page holds 200 of 471 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cullinan Therapeutics, Inc.’s releases · as of Nov 4, 2026

Common shares
64,920,924
Fully diluted
64,920,924

Fully diluted

LineSharesAs of
Common shares64,920,924Nov 4, 2026

Share count over time

CountShares
Nov 4, 202664,920,924

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Mpm Bioimpact LLC9.72MUS$149MSep 30, 2026
Lynx1 Capital Management LP8.96MUS$138MSep 30, 2026
Bvf Inc5.75MUS$88.3MSep 30, 2026
BlackRock5.32MUS$81.7MSep 30, 2026
T. Rowe Price4.09MUS$62.8MSep 30, 2026
Vanguard3.74MUS$57.4MSep 30, 2026
Kynam Capital Management, LP3.11MUS$47.8MSep 30, 2026
State Street2.6MUS$40MSep 30, 2026
Rtw Investments, LP2.36MUS$36.3MSep 30, 2026
Siren, L.L.C.1.79MUS$27.5MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Geode Capital1.45MUS$22.2MSep 30, 2026
Blue Owl Capital Holdings LP1.4MUS$21.5MSep 30, 2026
Venrock Adviser, LLC1.38MUS$21.2MSep 30, 2026
Dimensional1.08MUS$16.7MSep 30, 2026
Goldman Sachs989KUS$15.2MSep 30, 2026
Elmind Capital, LP963KUS$14.8MSep 30, 2026
Boothbay Fund Management, LLC953KUS$14.6MSep 30, 2026
Affinity Asset Advisors, LLC876KUS$13.4MSep 30, 2026
Fisher Asset Management, LLC801KUS$12.3MSep 30, 2026
Boone Capital Management LLC691KUS$10.6MSep 30, 2026
Morgan Stanley645KUS$9.9MSep 30, 2026
Twin Focus Capital Partners, LLC595KUS$9.14MSep 30, 2026
Northern Trust558KUS$8.57MSep 30, 2026
Schwab506KUS$7.77MSep 30, 2026
AQR Capital Management LLC499KUS$7.65MSep 30, 2026
Boxer Capital Management, LLC450KUS$6.91MSep 30, 2026
Bank of America416KUS$6.39MSep 30, 2026
TCG Crossover Management, LLC407KUS$6.24MSep 30, 2026
DWS378KUS$5.8MSep 30, 2026
Fidelity336KUS$5.16MSep 30, 2026
UBS325KUS$4.98MSep 30, 2026
Great Point Partners LLC300KUS$4.61MSep 30, 2026
Renaissance Technologies290KUS$4.45MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.286KUS$4.39MSep 30, 2026
Invesco283KUS$4.35MSep 30, 2026
JPMorgan273KUS$4.16MSep 30, 2026
Wellington263KUS$4.03MSep 30, 2026
Bleichroeder LP250KUS$3.84MSep 30, 2026
Two Sigma220KUS$3.37MSep 30, 2026
Trexquant Investment LP209KUS$3.21MSep 30, 2026
Susquehanna193KUS$2.96MSep 30, 2026
Apis Capital Advisors, LLC192KUS$2.95MSep 30, 2026
Moore Capital Management, LP181KUS$2.78MSep 30, 2026
Barclays178KUS$2.73MSep 30, 2026
HighVista Strategies LLC174KUS$2.67MSep 30, 2026
BNY173KUS$2.66MSep 30, 2026
Nuveen167KUS$2.56MSep 30, 2026
American Century159KUS$2.43MSep 30, 2026
Quantinno Capital Management LP121KUS$1.86MSep 30, 2026
PFM Health Sciences, LP105KUS$1.61MSep 30, 2026

This page holds 50 of 174 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2.38MUS$43.3MJun 30, 2026
Vanguard Total Stock Market Index Fund1.93MUS$35.1MJun 30, 2026
iShares Russell 2000 ETF1.58MUS$28.7MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.02MUS$18.6MJun 30, 2026
Fidelity Small Cap Index Fund661KUS$10.9MJul 31, 2026
Vanguard Extended Market Index Fund621KUS$11.3MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.584KUS$10.6MJun 30, 2026
iShares Russell 2000 Value ETF563KUS$10.2MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund560KUS$10.2MJun 30, 2026
iShares Biotechnology ETF319KUS$5.81MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Explorer Fund303KUS$5.01MJul 31, 2026
Nuveen Quant Small Cap Equity Fund302KUS$4.98MJul 31, 2026
Vanguard Russell 2000 Index Fund277KUS$4.56MMay 31, 2026
Fidelity Extended Market Index Fund267KUS$4.39MMay 31, 2026
Schwab U.S. Small-Cap ETF246KUS$4.05MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF211KUS$3.84MJun 30, 2026
iShares Micro-Cap ETF203KUS$3.69MJun 30, 2026
U.S. Micro Cap Portfolio196KUS$3.24MJul 31, 2026
Dimensional U.S. Small Cap ETF188KUS$3.11MJul 31, 2026
Dimensional U.S. Core Equity 2 ETF171KUS$2.82MJul 31, 2026
T. Rowe Price Small-Mid Cap ETF156KUS$2.85MJun 30, 2026
Schwab Small-Cap Index Fund147KUS$2.42MJul 31, 2026
U.S. Small Cap Portfolio143KUS$2.36MJul 31, 2026
Avantis U.S. Small Cap Equity ETF133KUS$2.19MMay 31, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund116KUS$2.11MJun 30, 2026
iShares U.S. Small-Cap Equity Factor ETF115KUS$1.9MJul 31, 2026
Vanguard U.S. Momentum Factor ETF115KUS$1.88MMay 31, 2026
Master Small Cap Index Series113KUS$2.06MJun 30, 2026
Vanguard Strategic Small-Cap Equity Fund104KUS$1.9MJun 30, 2026
Invesco Dorsey Wright SmallCap Momentum ETF103KUS$1.69MMay 31, 2026
Fidelity Total Market Index Fund97,554US$1.6MMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF93,627US$1.54MJul 31, 2026
Vanguard Health Care Index Fund88,087US$1.45MMay 31, 2026
Fidelity Small Cap Value Index Fund84,571US$1.54MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares80,791US$1.33MJul 31, 2026
Nuveen Small Cap Blend Index Fund80,186US$1.32MJul 31, 2026
Fidelity Series Total Market Index Fund78,550US$1.29MMay 31, 2026
JPMorgan Small Cap Value Fund76,920US$1.4MJun 30, 2026
Nuveen Equity Index Fund74,579US$1.23MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF72,163US$1.31MJun 30, 2026
EQ/2000 Managed Volatility Portfolio65,812US$1.2MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio63,185US$1.15MJun 30, 2026
Tema Oncology ETF62,826US$1.03MMay 31, 2026
Small Company Growth Portfolio54,308US$989KJun 30, 2026
JPMorgan U.S. Small Company Fund51,823US$944KJun 30, 2026
Bridge Builder Tax Managed Small/Mid Cap Fund51,795US$943KJun 30, 2026
U.S. Core Equity 2 Portfolio46,694US$770KJul 31, 2026
Transamerica T. Rowe Price Small Cap VP46,451US$846KJun 30, 2026
LVIP State Street Small-Cap Index Fund43,000US$783KJun 30, 2026
T. Rowe Price Health Sciences Portfolio42,900US$781KJun 30, 2026

This page holds 50 of 180 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Michaelson Jennifer
Officer: Chief Scientific Officer
Sale4,000USD 12.36US$49,440Nov 5, 2026
Michaelson Jennifer
Officer: Chief Scientific Officer
Sale8,000USD 21.57US$173KSep 8, 2026
Michaelson Jennifer
Officer: Chief Scientific Officer
Sale30,000USD 20.26US$608KAug 13, 2026
Michaelson Jennifer
Officer: Chief Scientific Officer
Sale8,000USD 17.82US$143KJul 6, 2026
Michaelson Jennifer
Officer: Chief Scientific Officer
Sale7,800USD 14.60US$114KMay 5, 2026
Michaelson Jennifer
Officer: Chief Scientific Officer
Sale200USD 15.58US$3,116May 5, 2026

Big stakes

StakeStakeSharesDateFiling
BVF PARTNERS L P/IL9.99%6.49MJun 30, 2026Schedule 13G
Lynx1 Capital Management LP9.80%5.77MSep 30, 2025Schedule 13G
T. Rowe Price Associates Inc6.20%3.83MJun 30, 2026Schedule 13G
Kynam Capital Management, LP5.27%3.11MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Stephen Webster
Other companies: NextCure, Inc. (Director · Since at least May 8, 2019); Gritstone bio, Inc. (Director · Apr 26, 2024 – Apr 4, 2025 · Past); Tcr2 Therapeutics Inc (Director · Apr 30, 2020 – Jun 1, 2023 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 2, 2022 · Past); Viking Therapeutics, Inc. (Director · Apr 28, 2015 – Jan 2, 2020 · Past); Spark Therapeutics Inc (CHIEF FINANCIAL OFFICER · Jan 29, 2015 – Dec 17, 2019 · Past); Optimer Pharmaceuticals Inc (Chief Financial Officer · Jun 25, 2012 – Oct 24, 2013 · Past); Adolor Corp (SVP, Finance & CFO · Sep 9, 2010 – Dec 12, 2011 · Past)
Chair of the Audit Committee · Since at least Jan 7, 2021
Owen Hughes
Other companies: AnaptysBio, Inc. (Member of the Audit Committee · Since at least May 11, 2026); XOMA Royalty Corporation (Chief Executive Officer, Director · Since at least Nov 11, 2024); C4 Therapeutics, Inc. (Director · Since at least Nov 16, 2023); ImageneBio, Inc. (Director · Dec 14, 2022 – Jun 7, 2024 · Past); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Radius Health, Inc. (Director · Apr 23, 2013 – Aug 15, 2022 · Past)
President and CEO, Director · Jan 7, 2021 – Jan 12, 2021 · Past
Mary Thistle
Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Oct 28, 2021); Q32 Bio Inc. (Director · Since at least Mar 27, 2018); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past)
Chair of the Compensation Committee · Since at least Aug 8, 2024
David Meek
Other companies: uniQure N.V. (Chairman of the Board · Since at least Feb 25, 2021); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past); Entasis Therapeutics Holdings Inc (Director · Jun 10, 2020 – Jul 7, 2022 · Past)
Director · Since at least May 15, 2024
Mary Kay Fenton
Other companies: Tourmaline Bio Inc. (Chief Financial Officer · May 6, 2021 – Jul 3, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Jun 23, 2022 · Past); Achillion Pharmaceuticals Inc (Chief Financial Officer · Dec 12, 2011 – Feb 9, 2018 · Past)
Chief Financial Officer · Since at least Apr 29, 2024
Nadim Ahmed
Other companies: Disc Medicine, Inc. (Director · Since at least Jul 14, 2025); Bristol-Myers Squibb Company (EVP and President, Hematology · Nov 20, 2019 – Dec 31, 2020 · Past); Celgene Corporation (PRES., GLOBAL HEM. AND ONC. · Jun 13, 2018 – Nov 20, 2019 · Past)
President and Chief Executive Officer · Since at least Oct 18, 2021
Morana Jovan-Embiricos
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Jul 29, 2020); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Feb 19, 2019 · Past)
Director · Jan 7, 2021 – Sep 16, 2021 · Past
Jeffrey Trigilio
Other companies: XOMA Royalty Corporation (Chief Financial Officer · Since at least Jan 12, 2026)
Chief Financial Officer · Jan 7, 2021 – Feb 22, 2024 · Past
Mittie Doyle
Other companies: Avalo Therapeutics, Inc. (Chief Medical Officer · Since at least Jul 15, 2024)
Director · Since at least Aug 7, 2025
Tony Rosenberg
Other companies: Radius Health, Inc. (Director · Feb 13, 2018 – Feb 26, 2020 · Past)
Director · Since at least Jan 7, 2021
All 17 people
PersonSeat
Andrew AllenMember of the Compensation Committee · Since at least Aug 7, 2025
Anne-Marie MartinDirector · Since at least Mar 1, 2022
Corrine SavillChief Business Officer · Since at least Jul 11, 2022
David P RyanDirector · Since at least Nov 1, 2022
Jeffrey Alan JonesChief Medical Officer · Since at least Feb 28, 2022
Nate NguyenInterim PAO and PFO · Mar 29, 2024 – Mar 29, 2024 · Past
Thomas EbelingDirector · Jan 7, 2021 – Jun 10, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Cullinan Therapeutics, Inc.